Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Experience matters with DES: The volume of drug-eluting coronary stent implants performed at a center is inversely related to the rates of myocardial infarction and death for the patients, according to data from the German Cypher Registry to be published in the Aug. 18 issue of Circulation. The analysis includes outcomes from 8,201 patients implanted with Johnson & Johnson/Cordis' Cypher sirolimus-eluting stents at 51 centers in Germany between April 2002 and September 2005. Centers that recruited over 400 sirolimus-eluting stent patients during the study period reported an all-cause mortality rate of 0.3% and a myocardial infarction rate of 0.5%. The death and MI rates for centers with between 150 and 400 Cypher patients were 0.6% and 1.2%, and the death and MI rates for centers with fewer than 150 Cypher patients were 0.7% and 1.7%

You may also be interested in...



Lannett Plans Seven Launches In Fiscal Year 2021

Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020. 

Pfizer Picks Up EU Pegfilgrastim Approval

Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.

A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”

AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.

Topics

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel